A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Besifovir (Primary) ; Levocarnitine; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Ildong Pharmaceutical
- 05 Jan 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jan 2020).
- 15 Oct 2021 Results of subset study (n=46) assessing changes of liver histology and intrahepatic covalently closed circular DNA (cccDNA) levels by Besifovir dipivoxil maleate treatment in comparison with tenofovir disoproxil fumarate therapy, published in the Journal of Gastroenterology and Hepatology
- 14 Apr 2018 Results over 96 week presented at The International Liver Congress 2018.